Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
J Clin Endocrinol Metab ; 108(9): 2203-2210, 2023 08 18.
Article in English | MEDLINE | ID: mdl-36916985

ABSTRACT

CONTEXT: Although adding spironolactone to renin-angiotensin system blockers reduces albuminuria in adults with chronic kidney disease and type 2 diabetes, it increases the risk of hyperkalemia. OBJECTIVE: To assess whether a lower dose of spironolactone (12.5 mg/d) reduces the risk of hyperkalemia while maintaining its effect on reducing albuminemia. DESIGN: Multicenter, open-label, randomized controlled trial. SETTING: This study was conducted from July 2016 to November 2020 in ambulatory care at 3 diabetes medical institutions in Japan. PATIENTS: We enrolled 130 Japanese adults with type 2 diabetes and albuminuria (≥30 mg/gCre), estimated glomerular filtration rate ≥30 mL/min/1.73 m2, and serum potassium level <5.0 mEq/L. INTERVENTIONS: The participants were randomly assigned to the spironolactone-administered and control groups. MAIN OUTCOME MEASURES: Changes in urine albumin-to-creatinine ratio (UACR) from baseline over the 24-week interventional period. RESULTS: The spironolactone group showed a significant reduction in UACR from baseline (mean decrease, 103.47 ± 340.80 mg/gCre) compared with the control group, which showed an increased UACR (mean increase, 63.93 ± 310.14 mg/gCre; P = .0007, Wilcoxon rank-sum test and t test). Although the spironolactone group had a statistically significant increase in serum potassium levels, none of the participants had a potassium level ≥5.5 mEq/L at 24 weeks. Further, participants with a higher initial serum potassium level tended to have a smaller increase (estimate, -0.37, analysis of covariance). CONCLUSIONS: Low-dose spironolactone administration reduced albuminuria without causing hyperkalemia. Spironolactone administration, the oldest known and most cost-effective mineralocorticoid receptor antagonist, at lower doses should be reconsidered.


Subject(s)
Diabetes Mellitus, Type 2 , Hyperkalemia , Renal Insufficiency, Chronic , Adult , Humans , Spironolactone/adverse effects , Hyperkalemia/chemically induced , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/urine , Albuminuria/drug therapy , Albuminuria/etiology , Mineralocorticoid Receptor Antagonists/adverse effects , Potassium , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/drug therapy
2.
J Clin Med Res ; 11(1): 15-20, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30627273

ABSTRACT

BACKGROUND: This prospective randomized, multicenter, open-label, comparative study was performed to analyze the effects of sitagliptin on glycemic control and maintenance of beta-cell function in patients with poorly controlled type 2 diabetes treated with low-dose glimepiride. METHODS: Forty-one patients with type 2 diabetes mellitus treated with low-dose glimepiride (≤ 2 mg/day) were prospectively enrolled in this study (age: 20 - 75 years; hemoglobin A1c (HbA1c): 7.4- 9.4%). The patients were randomized into two groups: the glimepiride (G) group, in which glimepiride dose was increased gradually to 6 mg/day, and the sitagliptin (S) group, in which sitagliptin was added at a dose of 50 mg/day. RESULTS: HbA1c level was significantly decreased after 24 weeks, but not 12 weeks, in the G group, while a significant decrease was seen after 12 weeks in the S group. Although there were no significant differences in HbA1c level at 24 weeks between the two groups (P = 0.057). The overall trend of changes in HbA1c level suggested that the glucose-lowering effects were superior in the S group. Furthermore, a significant change in fasting glucose was seen in the S group, but not in the G group. Glycemic control target was achieved in 36.7% and 16.7% patients in the S group and the G group, respectively. The proinsulin/insulin (P/I) ratio was significantly increased in the G group, whereas it tended to decrease in the S group. After 24 weeks of treatment, no significant difference was observed in the P/I ratio between the two groups, whereas a significant difference was noted in the ΔP/I (amount of change). Albuminuria tended to increase in the G group compared with the S group. CONCLUSION: The results of the present study suggested that sitagliptin effectively lowered hyperglycemia and that it may have a protective effect on pancreatic beta-cells when combined with a low dose of glimepiride. Therefore, sitagliptin may represent a useful combination therapy with low-dose sulfonylurea, not only for achieving glycemic control but also for protection of pancreatic beta-cells.

3.
J Diabetes Investig ; 6(6): 734-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26543549

ABSTRACT

We describe a case of type B insulin resistance syndrome associated with systemic lupus erythematosus (SLE) that was refractory to rituximab and successfully treated with a combination of oral glucocorticoids and cyclosporine. Prior to treatment, insulin resistance was severe, and application of a hyperinsulinemic euglycemic clamp was not possible despite the continuous intravenous infusion of insulin at a maximum rate of 9.0 mU/kg/min. The addition of cyclosporine to oral glucocorticoid therapy resulted in remission of insulin resistance. The combination of oral prednisolone and cyclosporine might be effective in treating type B insulin resistance syndrome, particularly in rituximab-resistant cases. However, nephrotoxicity is a particular concern for patients receiving long-term cyclosporine therapy.

4.
Endocr J ; 61(6): 589-95, 2014.
Article in English | MEDLINE | ID: mdl-24705560

ABSTRACT

A 67-year-old female with hypertension and impaired glucose tolerance was admitted to our hospital because of a typical acromegalic appearance, including large, thickened bulky hands and feet, and a large prominent forehead and tongue. She did not have a Cushingoid appearance, such as a moon-face, buffalo hump, purple striae or central obesity. The laboratory data revealed a serum GH level of 4.6 ng/mL and serum insulin-like growth factor-1 level of 811 ng/mL. The oral glucose tolerance test showed no suppression of the GH values. An endocrine examination showed a lack of circadian rhythmicity of ACTH and cortisol. Cortisol was not suppressed by a low dose of dexamethasone during the suppression test, but was suppressed by a high dose of dexamethasone. A radiological study revealed two isolated adenomas in the pituitary and a left adrenal tumor. These findings strongly suggested a diagnosis of acromegaly with subclinical Cushing's disease and a left adrenal incidentaloma. Transsphenoidal surgery was performed. Hematoxylin and eosin staining showed that the left and right pituitary adenomas were composed of basophilic and acidophilic cells, respectively. Immunohistochemical staining showed the left adenoma to be positive for ACTH and negative for GH. In contrast, the right adenoma was GH-positive and ACTH-negative. This is a rare case of independent double pituitary adenomas with distinct hormonal features. We also provide a review of the previously reported cases of double pituitary adenomas and discuss the etiology of these tumors.


Subject(s)
ACTH-Secreting Pituitary Adenoma/complications , Acromegaly/complications , Adenoma/complications , Adrenal Gland Neoplasms/complications , Growth Hormone-Secreting Pituitary Adenoma/complications , Pituitary ACTH Hypersecretion/complications , ACTH-Secreting Pituitary Adenoma/diagnosis , Acromegaly/diagnosis , Adenoma/diagnosis , Adrenal Gland Neoplasms/diagnosis , Aged , Asymptomatic Diseases , Female , Growth Hormone-Secreting Pituitary Adenoma/diagnosis , Humans , Pituitary ACTH Hypersecretion/diagnosis
5.
Endocr J ; 61(6): 561-70, 2014.
Article in English | MEDLINE | ID: mdl-24646676

ABSTRACT

µ-Crystallin (CRYM) is also known as NADPH-dependent cytosolic T3-binding protein. A study using CRYM-null mice suggested that CRYM stores triiodothyronine (T3) in tissues. We previously established CRYM-expressing cells derived from parental GH3 cells. To examine the precise regulation of T3-responsive genes in the presence of CRYM, we evaluated serial alterations of T3-responsive gene expression by changing pericellular T3 concentrations in the media. We estimated the constitutive expression of three T3-responsive genes, growth hormone (GH), deiodinase 1 (Dio1), and deiodinase 2 (Dio2), in two cell lines. Subsequently, we measured the responsiveness of these three genes at 4, 8, 16, and 24 h after adding various concentrations of T3. We also estimated the levels of these mRNAs 24 and 48 h after removing T3. The levels of constitutive expression of GH and Dio1 were low and high in C8 cells, respectively, while Dio2 expression was not significantly different between GH3 and C8 cells. When treated with T3, Dio2 expression was significantly enhanced in C8 cells, while there were no differences in GH or Dio1 expression between GH3 and C8 cell lines. In contrast, removal of T3 retained the mRNA expression of GH and Dio2 in C8 cells. These results suggest that CRYM expression increases and sustains the T3 responsiveness of genes in cells, especially with alteration of the pericellular T3 concentration. The heterogeneity of T3-related gene expression is dependent on cellular CRYM expression in cases of dynamic changes in pericellular T3 concentration.


Subject(s)
Crystallins/physiology , Gene Expression Regulation/drug effects , Triiodothyronine/metabolism , Triiodothyronine/pharmacology , Animals , Cells, Cultured , Crystallins/metabolism , Cytosol/metabolism , Growth Hormone/genetics , Growth Hormone/metabolism , Iodide Peroxidase/genetics , Iodide Peroxidase/metabolism , Mice , Rats , Somatotrophs/drug effects , Somatotrophs/metabolism , mu-Crystallins , Iodothyronine Deiodinase Type II
6.
Thyroid Res ; 5(1): 1, 2012 Jan 26.
Article in English | MEDLINE | ID: mdl-22280879

ABSTRACT

BACKGROUND: Similar to other systems, the endocrine system is affected by aging. Thyroid hormone, the action of which is affected by many factors, has been shown to be associated with longevity. The most useful marker for the assessment of thyroid hormone action is TSH level. Although age and gender are believed to modify the pituitary set point or response to free thyroid hormone concentration, the precise age- and gender-dependent responses to thyroid hormone have yet to be reported. METHODS: We analyzed the results of 3564 thyroid function tests obtained from patients who received medication at both out- and inpatient clinics of Shinshu University Hospital. Subjects were from among those with thyroid function test results in the normal or mildly abnormal range. Based on a log-linear relationship between the concentrations of FHs and TSH, we established the putative resistance index to assess the relation between serum FH and TSH levels. RESULTS: Free thyroid hormone and TSH concentration showed an inverse log-linear relation. In males, there was a negative relationship between the free T3 resistance index and age. In females, although there were no relationships between age and FHs, the indices were positively related to age. CONCLUSIONS: These findings indicated that there is a gender-specific response to thyroid hormone with aging. Although the TSH level is a useful marker for the assessment of peripheral thyroid hormone action, the values should be interpreted carefully, especially with regard to age- and gender-related differences.

7.
Med Princ Pract ; 21(2): 190-2, 2012.
Article in English | MEDLINE | ID: mdl-22095156

ABSTRACT

OBJECTIVE: To report a case of amiodarone-induced thyrotoxicosis (AIT) concomitant with thyroid cancer in multinodular goiter (MNG). CLINICAL PRESENTATION AND INTERVENTION: A 61-year-old man treated with amiodarone for 5 years presented with mild sweating. He was found to have AIT simultaneously with thyroid papillary cancer and MNG. Administration of amiodarone was stopped, and he was treated with methimazole for AIT. Five weeks after the initial treatment, thyroid function normalized. Total thyroidectomy was considered to enable use of amiodarone again. CONCLUSION: This case showed that thyrotoxicosis, MNG and amiodarone may contribute to thyroid carcinogenesis. Amiodarone should be carefully commenced in cases with MNG.


Subject(s)
Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Carcinoma, Papillary/complications , Goiter, Nodular/complications , Tachycardia, Ventricular/drug therapy , Thyroid Neoplasms/complications , Thyrotoxicosis/chemically induced , Amiodarone/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Carcinoma , Humans , Male , Middle Aged , Thyroid Cancer, Papillary
8.
Endocrine ; 40(3): 366-71, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21956518

ABSTRACT

Thyroid hormone secretion suppresses the expression of thyroid stimulating hormone (TSH), both of which are strictly controlled by a negative feedback loop between the hypothalamus-pituitary and thyroid. Pituitary resistance to thyroid hormone (PRTH) is defined as resistance to the action of thyroid hormone that is more severe in the pituitary than at the peripheral tissue level. Although the molecular basis of PRTH is not well understood, the clinical issue mainly involves imbalance between the hypothalamus-pituitary and peripheral thyroid hormone responsivity, which may induce peripheral thyrotoxic phenomena. Here, we review the pathogenesis and molecular aspects of PRTH, present a single case with inappropriate TSH secretion suffering from thyrotoxicosis treated with PTU, and discuss the possible choice of therapeutic options to correct the imbalance of thyroid hormone responsivity in both the hypothalamus-pituitary and peripheral tissues.


Subject(s)
Hypothalamo-Hypophyseal System/physiopathology , Pituitary Diseases , Pituitary Gland/physiopathology , Thyroid Hormones/physiology , Thyrotoxicosis/complications , Antithyroid Agents/therapeutic use , Feedback, Physiological , Humans , Male , Middle Aged , Pituitary Diseases/blood , Pituitary Diseases/complications , Pituitary Diseases/physiopathology , Pituitary Diseases/therapy , Propylthiouracil/therapeutic use , Thyroid Gland/physiology , Thyrotoxicosis/blood , Thyrotoxicosis/therapy , Thyrotropin/blood
9.
Intern Med ; 49(5): 403-7, 2010.
Article in English | MEDLINE | ID: mdl-20190473

ABSTRACT

We report two cases of type 1 diabetes mellitus (T1DM) which developed after interferon (IFN) therapy for chronic hepatitis C. The patients had experienced abrupt hyperglycemia with positive anti-glutamic acid decarboxylase antibodies, resulting in initiation of insulin therapy. In one case, insulin therapy could be discontinued because endogenous insulin secretion was preserved at the onset and pancreatic beta cell function was recovered thereafter. In the other case with Hashimoto's thyroiditis and Sjögren's syndrome, continuation of insulin therapy was necessary because blood glucose levels were unstably controlled. Lasting autoimmunity superior to immunosuppressive mechanism may be associated with distinct clinical courses in these cases.


Subject(s)
Diabetes Mellitus, Type 1/chemically induced , Hepatitis C, Chronic/drug therapy , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , Polyethylene Glycols/adverse effects , Polyethylene Glycols/therapeutic use , Aged , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/drug therapy , Female , Hashimoto Disease/blood , Hashimoto Disease/immunology , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Interferon alpha-2 , Middle Aged , Recombinant Proteins , Sjogren's Syndrome/blood , Sjogren's Syndrome/immunology
10.
Med Princ Pract ; 19(1): 79-81, 2010.
Article in English | MEDLINE | ID: mdl-19996626

ABSTRACT

OBJECTIVE: To report a case of infundibuloneurohypophysitis treated with steroid. CLINICAL PRESENTATION: A 65-year-old woman who was well until 4 weeks before admission and was not taking any medication presented with acute development of polydipsia and polyuria. Urinary volume was increased to 4,500 ml/day. She showed elevated serum osmolality and low urine osmolality, together with shortage of antidiuretic hormone. Magnetic resonance imaging (MRI) of the pituitary revealed marked nodular thickening of the neurohypophysis. Endocrinologically, anterior pituitary function appeared normal. Based on these examinations, she was diagnosed as having central diabetes insipidus due to lymphocytic infundibuloneurohypophysitis. INTERVENTION: Prednisolone (1 mg/kg/day, p.o.) and D-deaminovasopressin (5 microg/day, intranasal) were commenced. Ten days after the administration of the agents, MRI showed a dramatic improvement in the thickening of the neurohypophysis. Ten weeks later, abnormalities found in earlier MRI had disappeared. The drugs were withdrawn gradually, and diabetes insipidus ceased 25 weeks later. Recurrence was not seen in the subsequent MRI, and the function of the posterior pituitary gland was completely normalized even 7 years after discontinuation of treatments. CONCLUSION: This case shows that noninvasive diagnosis and appropriate steroid administration can effectively cure lymphocytic infundibuloneurohypophysitis; it is recommended with long-term follow-up.


Subject(s)
Diabetes Insipidus, Neurogenic/drug therapy , Pituitary Gland/pathology , Prednisolone/therapeutic use , Steroids/therapeutic use , Aged , Antiemetics/therapeutic use , Deamino Arginine Vasopressin/therapeutic use , Female , Humans , Magnetic Resonance Imaging
11.
Intern Med ; 48(6): 447-53, 2009.
Article in English | MEDLINE | ID: mdl-19293545

ABSTRACT

A 33-year-old woman was hospitalized for examination of edematous laryngopharynx. She was acromegalic. A pituitary adenoma with elevated serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) was detected, indicating acromegaly caused by GH-secreting pituitary adenoma. Multiple pigmented nevi were also noted without overt short stature and cubitus valgus. Chromosome analysis revealed that she had contracted Turner syndrome with 47,XXX/45,X/46,XX mosaicism. Transsphenoidal resection of the tumor decreased serum GH and IGF-I levels, but the edema was not improved. Both premature ovarian failure and hypertension appeared after surgery. This case may indicate the important relationships between GH/IGF-I and Turner syndrome.


Subject(s)
Acromegaly/genetics , Chromosomes, Human, X/genetics , Mosaicism , Turner Syndrome/genetics , Acromegaly/etiology , Adenoma/blood , Adenoma/complications , Adenoma/diagnosis , Adult , Diagnosis, Differential , Female , Growth Hormone/blood , Humans , In Situ Hybridization, Fluorescence , Magnetic Resonance Imaging , Pituitary Neoplasms/blood , Pituitary Neoplasms/complications , Pituitary Neoplasms/diagnosis , Turner Syndrome/complications
12.
Biochem Biophys Res Commun ; 374(4): 699-703, 2008 Oct 03.
Article in English | MEDLINE | ID: mdl-18680726

ABSTRACT

Migration and tube formation of endothelial cells are important in angiogenesis and require a coordinated response to the extra-cellular matrix (ECM) and growth factor. Since focal adhesion kinase (FAK) integrates signals from both ECM and growth factor, we investigated its role in angiogenesis. Type I and II collagens are fibril-forming collagens and stimulate human umbilical vein endothelial cells (HUVECs) to form tube structure. Although knockdown of FAK restrained cell motility and resulted in inhibition of tube formation, FAK degradation and tube formation occurred simultaneously after incubation with fibril-forming collagens. The compensation for the FAK degradation by a calpain inhibitor or transient over-expression of FAK resulted in disturbance of tube formation. These phenomena are specific to fibril-forming collagens and mediated via alpha2beta1 integrin. In conclusion, our data indicate that FAK is functioning in cell migration, but fibril-forming collagen-induced FAK degradation is necessary for endothelial tube formation.


Subject(s)
Cell Movement , Collagen Type II/metabolism , Collagen Type I/metabolism , Endothelium, Vascular/growth & development , Focal Adhesion Kinase 1/metabolism , Neovascularization, Physiologic , Animals , Cells, Cultured , Down-Regulation , Endothelium, Vascular/cytology , Focal Adhesion Kinase 1/antagonists & inhibitors , Gels , Humans , Rats
14.
Endocr J ; 54(2): 319-27, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17339748

ABSTRACT

High serum level of GH in the presence of low plasma level of insulin-like growth factor-I (IGF-I) is one of the endocrinological features of anorexia nervosa (AN). Whether the amount of endogenous GH is not enough to increase IGF-I is not certain. We studied the effect of recombinant human growth hormone (rhGH) on the GH-IGF-I axis and on malnutrition-related disorders in this syndrome. Twenty patients with AN were divided into two groups; one (N = 13) was given rhGH (0.33 mg/day), and the other (N = 7) was given placebo for 6 or 12 months, respectively. During each treatment, levels of serum GH, plasma IGF-I, serum thyroid hormones, serum cholesterol, fasting plasma glucose and cardiac function were monitored. Changes in body mass index (BMI) and calorie taken were also evaluated. Plasma IGF-I level increased from 74.4 +/- 41.9 to 269.0 +/- 31.2 microg/L (P<0.001) during administration of rhGH, which associated with a decrease in serum GH level from 17.0 +/- 15.0 to 1.6 +/- 0.8 microg/L (P<0.001). Administration of rhGH increased BMI, body temperature, fasting plasma glucose level, and food intake. Serum level of triiodothyronine, but not thyroxine, increased during treatment with rhGH. The treatment decreased serum levels of both total and HDL-cholesterol. Studies with echocardiography showed an increase in cardiac output during the treatment with rhGH. These improvements were not observed in patients treated with placebo. Administration of rhGH is recommended as one of the methods of managing the patients with AN.


Subject(s)
Anorexia Nervosa/complications , Human Growth Hormone/metabolism , Human Growth Hormone/therapeutic use , Insulin-Like Growth Factor I/metabolism , Malnutrition/drug therapy , Malnutrition/metabolism , Adult , Anorexia Nervosa/psychology , Attitude , Blood Glucose/metabolism , Body Mass Index , Body Temperature/drug effects , Cardiac Output/drug effects , Cholesterol/blood , Energy Intake/drug effects , Female , Human Growth Hormone/administration & dosage , Humans , Injections, Subcutaneous , Malnutrition/etiology , Malnutrition/pathology , Platelet Count , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Thyroid Hormones/blood , Treatment Outcome
15.
Biochem Biophys Res Commun ; 353(4): 895-901, 2007 Feb 23.
Article in English | MEDLINE | ID: mdl-17204240

ABSTRACT

Small heterodimer partner (SHP; NR0B2) is an orphan nuclear receptor and acts as a repressor for wide variety of nuclear hormone receptors. We demonstrated here that mouse SHP mRNA showed a circadian expression pattern in the liver. Transient transfection of the mSHP promoter demonstrated that CLOCK-BMAL1, core circadian clock components, bound to E-box (CACGTG), and stimulated the promoter activity by 4-fold. Liver receptor homologue-1 (LRH-1; NR5A2) stimulated the mSHP promoter, and CLOCK-BMAL1 synergistically enhanced the LRH-1-mediated transactivation. Interestingly, SHP did not affect the CLOCK-BMAL1-mediated promoter activity, but strongly repressed the synergistic activation of CLOCK-BMAL1 and LRH-1. Furthermore, in vitro pull-down assays revealed the existence of direct protein-protein interaction between LRH-1 and CLOCK. In summary, this study shows that CLOCK-BMAL1, LRH-1 and SHP coordinately regulate the mSHP gene to generate the circadian oscillation. The cyclic expression of mSHP may affect daily activity of other nuclear receptors and contribute to circadian liver functions.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , Promoter Regions, Genetic/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Trans-Activators/metabolism , ARNTL Transcription Factors , Animals , Basic Helix-Loop-Helix Transcription Factors/chemistry , Basic Helix-Loop-Helix Transcription Factors/genetics , CLOCK Proteins , COS Cells , Cell Line, Tumor , Chlorocebus aethiops , Circadian Rhythm , Dimerization , Electrophoretic Mobility Shift Assay , Gene Expression Regulation , Humans , Liver/metabolism , Luciferases/genetics , Luciferases/metabolism , Mice , Mice, Inbred ICR , Mutation , Protein Binding , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Trans-Activators/chemistry , Trans-Activators/genetics , Transfection
17.
Biochem Biophys Res Commun ; 351(1): 176-84, 2006 Dec 08.
Article in English | MEDLINE | ID: mdl-17054913

ABSTRACT

The expression of cholesterol 7alpha-hydroxylase (CYP7alpha), the rate-limiting enzyme in the catabolism of cholesterol to bile acid, is stimulated by oxysterol receptor, liver X receptor alpha (LXRalpha) and negatively regulated by a bile acid receptor, farnesoid X receptor. In the current study, we demonstrated that 1,25-(OH)(2)D3 blunted the LXRalpha-mediated induction of CYP7alpha mRNA in H4IIE rat hepatoma cells. In co-transfection experiments in HepG2 cells, VDR repressed the activity of rat CYP7alpha promoter in a ligand-dependent manner through inhibition of LXRalpha signaling. We also confirmed the ability of VDR to repress LXRalpha transcriptional activation using a synthetic LXRalpha responsive reporter. Deletion analyses revealed that the ligand-binding domain of VDR was required for the suppression and the DNA-binding domain was dispensable. Given the fact that VDR can be activated by the secondary bile acid as well as 1,25-(OH)(2)D3, the crosstalk between LXRalpha and VDR signaling in regulation of bile acid metabolism provides a possible contribution of VDR to modulate bile acid and cholesterol homeostasis, and highlights a physiological function of VDR beyond calcium metabolism in the body.


Subject(s)
Calcitriol/analogs & derivatives , Carcinoma, Hepatocellular/metabolism , Cholesterol 7-alpha-Hydroxylase/metabolism , DNA-Binding Proteins/metabolism , Receptors, Calcitriol/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/physiology , Animals , Bile Acids and Salts , COS Cells , Calcitriol/pharmacology , Cell Line , Chlorocebus aethiops , Humans , Liver X Receptors , Orphan Nuclear Receptors , Rats , Signal Transduction/drug effects
18.
J Endocrinol ; 182(2): 295-302, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15283690

ABSTRACT

Thyroid hormone receptors (TR) are members of the nuclear receptor superfamily. There are at least two TR isoforms, TRalpha and TRbeta, which act as mediators of thyroid hormone in tissues. However, the relative expression of each TR isoform in target tissues is still elusive. Herein, we have developed an RT-PCR and restriction enzyme digestion method to determine the expression of TRalpha1 and TRbeta1. We analyzed the expression of TR isoforms in 3T3-L1 preadipocytes induced to differentiate by an adipogenic cocktail in the presence or absence of 100 nM triiodothyronine (T(3)). The TRalpha1 isoform was predominantly expressed in 3T3-L1 adipocytes, and its expression was increased at the stage of development concomitant with the emergence of lipid droplets. Little, if any, TRbeta1 mRNA was detected in adipocytes. Administration of T(3) to the differentiating 3T3-L1 cells enhanced the accumulation of triglyceride. The expression profile of TRalpha1 in T(3)-treated adipocytes was similar to that in non-treated cells. The transcripts of adipogenic factors, CCAAT/enhancer binding protein beta (C/EBPbeta) and peroxisome proliferator activated receptor gamma (PPARgamma), were not altered by T(3). Lipid binding protein, aP2, that is downstream of these transcription factors was also unaffected by T(3). In contrast, the lipogenic enzyme, glyceraldehyde-3-phosphate dehydrogenase mRNA was significantly increased in the presence of T(3). Therefore, T(3) appears to be a hormone capable of modulating the expression of lipogenic enzyme and augments the accumulation of lipid droplets. We conclude that the TRalpha isoform might play an important role in the generation and maintenance of the mature adipocyte phenotype, regulating the expression of lipogenic enzymes.


Subject(s)
Adipocytes/metabolism , Lipids/biosynthesis , Thyroid Hormone Receptors alpha/analysis , Triglycerides/metabolism , Triiodothyronine/pharmacology , 3T3 Cells , Adipocytes/drug effects , Animals , Cell Differentiation , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Mice , Reverse Transcriptase Polymerase Chain Reaction
19.
Cancer Gene Ther ; 11(1): 8-15, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14681722

ABSTRACT

The present treatment of advanced and metastatic medullary thyroid carcinoma (MTC) is unsatisfactory. Tissue-specific cancer gene therapy is a novel alternative approach. We developed a recombinant adenovirus expressing Herpes simplex type 1 thymidine kinase (HSVtk) driven by a modified CALC-I promoter TCP (AdTCPtk). Infection with this virus showed efficient cytotoxic effect on MTC cell lines (rMTC and TT cells) after treatment with ganciclovir (GCV) in vitro. In a syngenic WAG/Rij rat model, the combination of AdTCPtk/GCV treatment with administration of murine interleukin-12 (mIL-12) expressing adenovirus under control of TCP (AdTCPmIL-12) resulted in effective growth suppression of tumor at the treated site and also at a distant untreated site, in comparison to treatment with AdTCPtk/GCV or AdTCPmIL-12 alone. Moreover, intravenous injection of AdTCPtk, or AdTCPtk+AdTCPmIL-12, followed by administration of GCV, did not cause evident toxicity after administration of GCV. These results indicate that this combined system can provide an effective therapy for metastatic MTC with minimal toxicity.


Subject(s)
Carcinoma, Medullary/genetics , Carcinoma, Medullary/therapy , Ganciclovir/pharmacology , Genetic Therapy/methods , Interleukin-12/therapeutic use , Thymidine Kinase/metabolism , Thyroid Neoplasms/genetics , Thyroid Neoplasms/therapy , Adenoviridae/genetics , Animals , Carcinoma, Medullary/pathology , Cell Division , Cell Line, Tumor , Ganciclovir/adverse effects , Ganciclovir/therapeutic use , Humans , Interleukin-12/adverse effects , Interleukin-12/genetics , Mice , Neoplasm Transplantation , Organ Specificity , Rats , Simplexvirus/enzymology , Simplexvirus/genetics , Thymidine Kinase/adverse effects , Thymidine Kinase/genetics , Thyroid Neoplasms/pathology
20.
Biochem Biophys Res Commun ; 312(2): 513-9, 2003 Dec 12.
Article in English | MEDLINE | ID: mdl-14637167

ABSTRACT

Peroxisome proliferator-activated receptors (PPARs) are nuclear fatty acid receptors that have been implicated to play an important role in lipid and glucose homeostasis. PPARalpha potentiates fatty acid catabolism in the liver and is activated by the lipid-lowering fibrates, whereas PPARgamma is essential for adipocyte differentiation. Here we report that nuclear vitamin D(3) receptor (VDR) represses the transcriptional activity of PPARalpha but not PPARgamma in a 1,25(OH)(2)D(3)-dependent manner. The analysis using chimeric receptors revealed that ligand binding domain of PPARalpha and VDR was involved in the molecular basis of this functional interaction and that the DNA binding domain of VDR was not required for the suppression, suggesting a novel mechanism that might involve protein-protein interactions rather than a direct DNA binding. Furthermore, the treatment of rat hepatoma H4IIE cells with 1,25(OH)(2)D(3) diminishes the induction of AOX mRNA by PPARalpha ligands, Wy14,643. VDR signaling might be considered as a factor regulating lipid metabolism via PPARalpha pathway. We report here the novel action of VDR in controlling gene expression through PPARalpha signaling.


Subject(s)
Calcitriol/pharmacology , Gene Expression Regulation/physiology , Receptors, Calcitriol/metabolism , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/physiology , Transcription Factors/antagonists & inhibitors , Transcription Factors/metabolism , Animals , COS Cells , Chlorocebus aethiops , Dose-Response Relationship, Drug , Receptors, Cytoplasmic and Nuclear/classification , Transcription Factors/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...